After Abeta Blow, Biogen And Eisai Get BACE Boost

 
• By Eleanor Malone

Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.

Caution
BACE inhibitors have not fared well in the clinic

More from Neurological

More from Therapy Areas